TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05766553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality pod
Description: The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patches and chewing gum
Description: Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
Study: NCT06558240

Intervention type: DEVICE
Intervention: HERADERM Hydrogel Wound Dressing (Sterile)
Description: HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
Study: NCT06360887

Intervention type: PROCEDURE
Intervention: Conservative
Description: Conservative treatment

Intervention type: PROCEDURE
Intervention: ORIF
Description: Open surgery

Intervention type: PROCEDURE
Intervention: CRPP
Description: Minimal invasive surgery
Study: NCT06012812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection
Description: SHR-1819 injection 300 mg Q2W
Study: NCT05784740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week precision exercise training
Description: The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
Study: NCT05255614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality Simulator
Description: LapSim is a device designed by Surgical Science Device \& software at Swedan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality Simulator
Description: LapSim is a device designed by Surgical Science Device \& software at Swedan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic trainer:
Description: Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic trainer:
Description: Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
Study: NCT06318962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aviva
Description: Digital phone app for BCBT
Study: NCT05563480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
Description: Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection; Penpulimab injection
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study: NCT01539265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05914753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
Description: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin, Cyclophosphamide, Docetaxel
Description: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
Study: NCT05372315

Intervention type: DRUG
Group type: OTHER
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: (dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: (dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
Study: NCT06136039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Sarcopenia)
Description: Same as standard treatment
Study: NCT05853627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory reactivation procedures
Description: In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory reactivation procedures
Description: In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
Study: NCT05104775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-035
Description: Administration by intravenous infusion.
Study: NCT05632562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Description: High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
Study: NCT05783258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with CAF+tSCTG
Description: Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery with CAF+L-PRF
Description: Coronally advanced flap and L-PRF membranes
Study: NCT06525220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petosemtamab
Description: MCLA-158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Humanized Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized Antibody
Study: NCT06251479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral 1
Description: verbal and non verbal tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral 2
Description: verbal and non verbal tasks with other partecipants
Study: NCT05773040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-213
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-213
Description: Given by (IV) vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given by IV (vein)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given by IV (vein)
Study: NCT05610280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT05086172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrabrief Behavioral Activation
Description: The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
Study: NCT05460988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap surgery
Description: All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical re-instrumentation
Description: The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
Study: NCT06378255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycation-based new dentinal desensitizer
Description: Dental desensitization treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: GLUMA desensitizer
Description: Dental desensitization treatment
Study: NCT05775575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Study: NCT06136039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm II(Normal)
Description: Same as standard treatment
Study: NCT06251479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromodulation 1
Description: registration with neurophysiological tecniques during verbal and non verbal tasks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromodulation 2
Description: registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
Study: NCT05675605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-1091
Description: TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-1091
Description: TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
Study: NCT04231643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: one-time oral administration of 5 mg dronabinol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: one-time oral administration of 5 mg dronabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: one-time oral administration of 600 mg Epidiolex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex
Description: one-time oral administration of 600 mg Epidiolex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: one-time oral administration of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: one-time oral administration of placebo
Study: NCT05249855

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological measurement
Description: Psychological assessment
Study: NCT04807868

Intervention type: PROCEDURE
Intervention: Standard of care liver biopsy
Description: Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.

Intervention type: OTHER
Intervention: Fibroscan
Description: A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.

Intervention type: OTHER
Intervention: Fibroscan
Description: A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
Study: NCT05537363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
Study: NCT05701852

Intervention type: OTHER
Intervention: reward learning task
Description: during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.

Intervention type: OTHER
Intervention: reward learning task
Description: during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
Study: NCT06003933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 10 ml of 0.25% bupivacaine on each side of cervical region at C5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10ml xylocaine on each side of cervical region at C5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
Study: NCT05767905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment A
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment A
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment B
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment B
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment C
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment C
Description: A single dose of PF-06821497 administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment D
Description: A single dose of PF-06821497 administered under fasting conditions.
Study: NCT04807868

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Blood and urine will be collected.
Study: NCT05767905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment E
Description: A single dose of PF-06821497 administered after low fat meal
Study: NCT05001555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Vitamin B
Description: 1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
Study: NCT05767905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment F
Description: A single dose of PF-06821497 administered after high fat meal.